​Eight new things keeping Vertex Pharmaceuticals up at night in 2016

New competitors. Comments by presidential candidates. Recent collaborations. Potential changes to corporate tax laws. Those are some of the new things top executives at Vertex Pharmaceuticals (Nasdaq: VRTX) revealed as potential “risk factors” in the company’s most recent annual report. The 1,950-employee company saw considerable changes over the past year with the launch of Orkambi, its new cystic fibrosis drug, which is expected to take over as the firm’s biggest moneymaker in the next…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news